CMPI - CMPI STOCK NEWS

Checkmate Pharmaceuticals (NASDAQ: CMPI) has initiated patient dosing in the anti-PD-1 refractory cutaneous squamous cell carcinoma (CSCC) arm of a Phase 2 study evaluating vidutolimod combined with cemiplimab. This trial marks a significant advancement for addressing untreated cases of this life-threatening skin cancer. Interim CEO Alan Fuhrman emphasized the importance of this trial as part of the company's strategy to broaden treatment possibilities for patients suffering from CSCC.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced that Alan Fuhrman, Interim CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The pre-recorded webcast will be accessible on-demand from November 22 to December 2, 2021, at 10:00 am ET. Additionally, the company will conduct 1x1 investor meetings during the conference. Checkmate focuses on leveraging its proprietary technology to enhance the immune system's ability to fight cancer, with its main product candidate, vidutolimod (CMP-001), being a TLR9 agonist aimed at tumor attacks.

Checkmate Pharmaceuticals (CMPI) announced its third quarter 2021 financial results and interim leadership changes, appointing Alan Fuhrman as President and CEO. The company is advancing clinical trials for vidutolimod in melanoma and head and neck cancers, with data readouts expected in 2022. Financial highlights include R&D expenses increasing to $11.4 million from $6.7 million year-over-year, and G&A expenses rising to $3.6 million from $3.2 million. As of September 30, 2021, Checkmate had $80.8 million in cash and investments.

Checkmate Pharmaceuticals (CMPI) announced promising results from its Phase 1b study of vidutolimod at the SITC Annual Meeting. The trial showed an overall response rate (ORR) of 23.5% when vidutolimod was combined with pembrolizumab, and 20.0% as a monotherapy. The combination therapy demonstrated a median duration of response of 25.2 months, indicating significant systemic antitumor activity in patients with PD-1 blockade-refractory melanoma. Safety monitoring indicated the treatment was well tolerated, with common side effects including chills and fatigue.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced that Dr. James Wooldridge, Chief Medical Officer, will present a pre-recorded webcast at the Jefferies London Healthcare Conference, scheduled from November 16-19, 2021. The presentation will be available on-demand starting November 18 at 3:00am ET until November 19 at 12:00pm ET. In addition, Checkmate will hold one-on-one investor meetings during the event. Information about the webcast can be found on the Checkmate website.

Checkmate focuses on utilizing its proprietary technology to leverage the immune system to combat cancer.

Checkmate Pharmaceuticals (CMPI) announced that final clinical data from its Phase 1b study of vidutolimod will be presented at the SITC Annual Meeting on November 12, 2021. The study investigates the efficacy of vidutolimod, a TLR9 agonist, administered alone and in combination with pembrolizumab for patients with PD-1 blockade–refractory melanoma. The presentation will be made by John M. Kirkwood, highlighting significant findings which could impact future trials and treatments in oncology.

Checkmate Pharmaceuticals has appointed Alan Fuhrman as interim President and CEO, succeeding Barry Labinger. Fuhrman, an experienced biotech executive, aims to advance the clinical program for vidutolimod, a potential treatment for melanoma and other tumors. The company is currently searching for a permanent CEO. The announcement highlights Checkmate's commitment to harnessing the immune system against cancer. Notably, Checkmate is a clinical-stage biopharmaceutical firm focusing on innovative cancer therapies.

Checkmate Pharmaceuticals, a clinical stage biopharmaceutical company (Nasdaq: CMPI), announced a live webcast on innate immune modulators and its product vidutolimod (CMP-001) on October 26, 2021. The event, moderated by Jefferies, features Dr. Jason Luke and Dr. Art Krieg discussing the potential of innate immune modulation in cancer therapy, specifically targeting melanoma and other cancers. Vidutolimod, an advanced TLR9 agonist, is currently in late-stage trials. An archived version of the webcast will be available for 90 days on Checkmate's website.

Checkmate Pharmaceuticals (NASDAQ: CMPI) announced that CEO Barry Labinger will present at the Cantor Virtual Global Healthcare Conference on September 30, 2021, from 10:40-11:10 AM ET. The event will include 1x1 investor meetings and a webcast available on Checkmate's website. The company focuses on developing proprietary technology to enhance the immune system's ability to fight cancer, particularly through its product candidate, vidutolimod (CMP-001), a therapeutic designed to activate the body's innate immune response. More information is available online.